REG - Venture Life Group - Director/PDMR Shareholding <Origin Href="QuoteRef">VLG.L</Origin>
RNS Number : 1559BVenture Life Group PLC14 June 2016Venture Life Group PLC
("Venture Life" or the "Company")
Director/PDMR Shareholding
Bracknell, UK - 14 June 2016: Venture Life Group plc (AIM: VLG), the international consumer healthcare group addressing the self-care needs of the ageing population, announces that it was informed on 13 June 2016 that Ms. Sharon Collins, the Commercial Director of the Company, has undertaken dealings in 27,030 ordinary shares of 0.3p each in the Company ("Ordinary Shares"), transferring 26,430 of her current holding of Ordinary Shares to her ISA, and selling and re-purchasing 600 Ordinary Shares to be held in her non-ISA account.
The dealings were made between 8 June 2016 and 13 June 2016 as set out below:
Date
Dealing type
Number of Ordinary Shares sold
Number of Ordinary Shares purchased
Price (p)
8 June 2016
Sale
26,600
-
57.00
8 June 2016
Purchased to ISA
-
26,000
57.10
9 June 2016
Sale
430
-
57.00
9 June 2016
Purchased to ISA
-
430
57.00
Total sold
27,030
-
Total purchased to ISA
-
26,430
13 June 2016
Purchase
-
600
59.49
Total dealings
27,030
27,030
Following the dealings, Ms. Collins's beneficial interest in the Company remains unchanged at 1,582,417 Ordinary Shares, representing approximately 4.3% of the issued share capital in the Company.
For further information please contact:
Venture Life Group PLC
Jerry Randall, Chief Executive Officer +44 (0)1344 742 870
James Hunter, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Freddy Crossley +44 (0) 20 7886 2500Peter Steel
Duncan Monteith
Corporate FinanceTom Salvesen
Corporate BrokingSquare1 Consulting
David Bick
Brian Alexander +44 (0)20 7929 5599
About Venture Life
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin.
The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.
Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
This information is provided by RNSThe company news service from the London Stock ExchangeENDDSHLLFLLRDISLIR
Recent news on Venture Life
See all newsREG - Venture Life Group - RCF in Place and New Partner in the USA
AnnouncementREG - Venture Life Group - Final Results for year ended 31 December 2023
AnnouncementREG - Venture Life Group - Notice of Results and Investor Presentation
AnnouncementREG - Venture Life Group - Holding(s) in Company
AnnouncementREG - Venture Life Group - Holding(s) in Company
Announcement